Takotsubo cardiomyopathy concurrent with hyperthyroidism following COVID-19—a case report and literature review
-
By
-
Liya Lin
-
Shanshan Liu
-
Yi Fang
-
Qijing Zhou
-
Minyue Jia
-
Hanxiao Yu
-
Kai Cheok
-
Xuehua Zhang
-
Lingxia Ye
-
Xiaoxiao Song
-
July 8, 2026
-
Clinical Scorecard: Takotsubo Cardiomyopathy Associated with Hyperthyroidism After COVID-19: A Case Study and Review of Existing Literature
At a Glance
| Category | Detail |
|---|
| Condition | Takotsubo Cardiomyopathy |
| Key Mechanisms | Viral infection, autoimmune thyroid disease, and cardiovascular vulnerability leading to myocardial stress. |
| Target Population | Patients with recent SARS-CoV-2 infection presenting with cardiac symptoms. |
| Care Setting | Emergency and cardiology settings for acute cardiac evaluation. |
Key Highlights
- Case of a 21-year-old male with TTS following COVID-19 and hyperthyroidism.
- Diagnosis confirmed through ECG, echocardiography, and coronary angiography.
- Treatment with methimazole and beta-blockers resulted in resolution of cardiac dysfunction.
Guideline-Based Recommendations
Diagnosis
- Use imaging modalities such as echocardiography and cardiac magnetic resonance to confirm TTS.
Management
- Consider thyroid evaluation in COVID-19 patients with cardiac symptoms.
Monitoring & Follow-up
- Monitor thyroid function and cardiac status during treatment.
Risks
- Potential exacerbation of autoimmune thyroid dysfunction post-COVID-19.
Patient & Prescribing Data
Young adults with no prior history of thyroid disease.
Methimazole and beta-blockers were effective in managing symptoms.
Clinical Best Practices
- Integrate management of viral, endocrine, and cardiovascular aspects in TTS cases.
Related Resources & Content
